Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $237,907.12 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Annette Bruls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Edwards Lifesciences Stock Performance

EW traded up $0.24 during trading hours on Friday, hitting $90.19. The company’s stock had a trading volume of 2,043,685 shares, compared to its average volume of 4,699,688. The company has a 50-day simple moving average of $89.48 and a 200 day simple moving average of $84.99. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $51.93 billion, a PE ratio of 51.83, a PEG ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. UBS Group initiated coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Institutional Trading of Edwards Lifesciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP lifted its stake in Edwards Lifesciences by 1,028.9% during the second quarter. Corient Private Wealth LP now owns 250,101 shares of the medical research company’s stock valued at $22,624,000 after buying an additional 227,947 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Edwards Lifesciences by 1.4% in the second quarter. HighTower Advisors LLC now owns 149,485 shares of the medical research company’s stock worth $13,522,000 after acquiring an additional 2,101 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Edwards Lifesciences in the second quarter worth approximately $61,441,000. Vancity Investment Management Ltd raised its holdings in shares of Edwards Lifesciences by 15.8% during the second quarter. Vancity Investment Management Ltd now owns 167,876 shares of the medical research company’s stock valued at $15,186,000 after acquiring an additional 22,881 shares during the period. Finally, California State Teachers Retirement System raised its holdings in shares of Edwards Lifesciences by 9,187.8% during the second quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock valued at $7,323,828,000 after acquiring an additional 80,090,362 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.